Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Pathlab & DiagnosticsBOM:540788 -1.97%51 Current Ratio is 1.43 as of Mar. 2026, which is 15% below its 10-year median of 1.68. GuruFocus rates BOM:540788 with a GF Score™ of 51/100 and a GF Value™ of ₹70.73 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 212 Medical Diagnostics & Research companies, Aspira Pathlab & Diagnostics ranks worse than 67.92% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Aspira Pathlab & Diagnostics's current ratio for the quarter that ended in Mar. 2026 was 1.43.
Aspira Pathlab & Diagnostics has a current ratio of 1.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for Aspira Pathlab & Diagnostics's Current Ratio or its related term are showing as below:
BOM:540788'
s Current Ratio Range Over the Past 10 Years
Min: 0.55 Med: 1.68 Max: 3.99
Current: 1.43
During the past 13 years, Aspira Pathlab & Diagnostics's highest Current Ratio was 3.99. The lowest was 0.55. And the median was 1.68.
BOM:540788's Current Ratio is ranked worse than 67.92% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.13
vs BOM:540788: 1.43
Aspira Pathlab & Diagnostics (BOM:540788) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Aspira Pathlab & Diagnostics Current Ratio Related Terms
Aspira Pathlab & Diagnostics Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540788 vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Aspira Pathlab & Diagnostics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Pathlab & Diagnostics Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Pathlab & Diagnostics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Aspira Pathlab & Diagnostics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Pathlab & Diagnostics (BOM:540788) has a Current Ratio of 1.43 as of Mar. 2026. This is 15% below median its historical median of 1.68. Over the past decade, Aspira Pathlab & Diagnostics' Current Ratio has ranged from 0.55 to 3.99. According to the industry distribution chart, Aspira Pathlab & Diagnostics ranks #144 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 67.9%.
Is Aspira Pathlab & Diagnostics' Current Ratio too high?
Aspira Pathlab & Diagnostics' current Current Ratio of 1.43 is 15% below median its 10-year median of 1.68. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 3.99. The Medical Diagnostics & Research industry median Current Ratio is 2.13. Aspira Pathlab & Diagnostics' value of 1.43 is 32.9% below this industry median. Based on the distribution chart, Aspira Pathlab & Diagnostics ranks #144 out of 212 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Pathlab & Diagnostics ranks #144 out of 212 companies for Current Ratio. This places Aspira Pathlab & Diagnostics in the lower half of its industry. The industry median Current Ratio is 2.13. Aspira Pathlab & Diagnostics' value of 1.43 is 32.9% below this benchmark. Historically, Aspira Pathlab & Diagnostics' own Current Ratio has ranged from 0.55 to 3.99 over the past decade. While the company's 10-year median is 1.68 vs. the industry median of 2.13, Aspira Pathlab & Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.13, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Pathlab & Diagnostics's current Current Ratio of 1.43 is 32.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Pathlab & Diagnostics's current Current Ratio is 1.43, which is 15% below median its own 10-year median of 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹70.73, compared to a current price of ₹106.90 — trading 51.1% above its estimated fair value. The current Current Ratio is 1.43, which is 15% below median its 10-year median of 1.68 and 32.9% below the Medical Diagnostics & Research industry median of 2.13. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current Current Ratio is 1.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹106.90 is trading 51.1% above its estimated GF Value™ of ₹70.73.
GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.
Key valuation signals for BOM:540788:
Current Ratio: 1.43 (15% below median its 10-year median of 1.68)
GF Value™: ₹70.73 vs. price of ₹106.90 (51.1% above fair value)
Industry Position: 32.9% below the Medical Diagnostics & Research median (#144 of 212)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score
Get the complete analysis for BOM:540788
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
